Back to top
more

OPKO Health (OPK)

(Delayed Data from NSDQ)

$1.26 USD

1.26
3,664,499

-0.01 (-0.79%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $1.27 +0.01 (0.79%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Implied Volatility Surging for OPKO Health (OPK) Stock Options

by Zacks Equity Research

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Zacks Equity Research

Is the Options Market Predicting a Spike in OPKO Health (OPK) Stock?

by Zacks Equity Research

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Zacks Equity Research

Here's Why You Should Retain OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.

Zacks Equity Research

Why Is OPKO Health (OPK) Down 2.6% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.

Zacks Equity Research

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline

by Zacks Equity Research

OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Do Options Traders Know Something About OPKO Health (OPK) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Zacks Equity Research

Why Is OPKO Health (OPK) Down 6.7% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Do Options Traders Know Something About OPKO Health (OPK) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.

Zacks Equity Research

OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates

by Zacks Equity Research

Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.

Sanghamitra Saha headshot

Bet on Top Stocks With Rising P/E to Enjoy Solid Gains

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Zacks Equity Research

OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -100.00% and -9.97%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Is OPKO Health (OPK) Down 0.8% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues

by Zacks Equity Research

OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.

Zacks Equity Research

Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now

by Zacks Equity Research

Strong contribution from Impella product line is likely to provide Abiomed (ABMD) a competitive edge in the MedTech space.

Zacks Equity Research

Varian Medical's (VAR) ProBeam Compact Picked by Biopolis

by Zacks Equity Research

The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.

Zacks Equity Research

Cerner Picked by Remi Vista for Behavioral Health Technology

by Zacks Equity Research

Apart from Cerner Integrated, Cerner's (CERN) revenue cycle solutions will help Remi Vista's financial operations.

Zacks Equity Research

Here's Why Investors Should Retain athenahealth (ATHN) Stock

by Zacks Equity Research

athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.

Zacks Equity Research

Allscripts Selected by Premier for Connected Health Platform

by Zacks Equity Research

Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.

Zacks Equity Research

Here's Why You Should Invest in OPKO Health (OPK) Right Now

by Zacks Equity Research

OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why Investors Should Hold Patterson Companies Stock

by Zacks Equity Research

Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.

Zacks Equity Research

Here's Why Investors Should Hold McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.

Zacks Equity Research

Cerner & Christiana Care Unite to Offer Bariatric Services

by Zacks Equity Research

Cerner (CERN) likely to gain from increased obesity rates in the United States.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.